Lipocine Inc. (LPCN)
LPCN Stock Price Chart
Explore Lipocine Inc. interactive price chart. Choose custom timeframes to analyze LPCN price movements and trends.
LPCN Company Profile
Discover essential business fundamentals and corporate details for Lipocine Inc. (LPCN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
22 Oct 2013
Employees
16.00
Website
https://www.lipocine.comCEO
Mahesh V. Patel
Description
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.
LPCN Financial Timeline
Browse a chronological timeline of Lipocine Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.56.
Earnings released on 5 Aug 2025
EPS came in at -$0.41 matching the estimated -$0.41, while revenue for the quarter reached $622.85K , beating expectations by +161.70%.
Earnings released on 8 May 2025
EPS came in at -$0.35 matching the estimated -$0.35, while revenue for the quarter reached $93.86K , missing expectations by -73.33%.
Earnings released on 13 Mar 2025
EPS came in at $0.33 surpassing the estimated -$0.40 by +182.50%, while revenue for the quarter reached $3.49M , beating expectations by +33.57%.
Earnings released on 7 Nov 2024
EPS came in at -$0.44 surpassing the estimated -$0.48 by +8.33%.
Earnings released on 8 Aug 2024
EPS came in at -$0.56 surpassing the estimated -$0.78 by +28.21%, while revenue for the quarter reached $89.57K , missing expectations by -69.12%.
Earnings released on 9 May 2024
EPS came in at $0.66 surpassing the estimated -$0.68 by +197.06%, while revenue for the quarter reached $7.62M .
Earnings released on 7 Mar 2024
EPS came in at -$0.42 surpassing the estimated -$0.53 by +20.75%, while revenue for the quarter reached $216.19K .
Earnings released on 8 Nov 2023
EPS came in at -$1.27 falling short of the estimated -$0.57 by -122.81%, while revenue for the quarter reached -$3.12M , missing expectations by -1.12K%.
Earnings released on 10 Aug 2023
EPS came in at -$0.68 falling short of the estimated -$0.64 by -6.25%.
Stock split effective on 12 May 2023
Shares were split 1 : 17 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 11 May 2023
EPS came in at -$0.68 falling short of the estimated -$0.42 by -61.90%, while revenue for the quarter reached $54.99K , missing expectations by -92.95%.
Earnings released on 10 Mar 2023
EPS came in at -$0.51 falling short of the estimated $0.03 by -1.80K%, while revenue for the quarter reached $500.00K , missing expectations by -61.83%.
Earnings released on 9 Nov 2022
EPS came in at -$0.51 matching the estimated -$0.51.
Earnings released on 8 Aug 2022
EPS came in at -$0.68 matching the estimated -$0.68, while revenue for the quarter reached $500.00K , beating expectations by +94.55%.
Earnings released on 9 May 2022
EPS came in at -$0.68 falling short of the estimated -$0.34 by -100.00%.
Earnings released on 9 Mar 2022
EPS came in at $2.55 surpassing the estimated -$0.85 by +400.00%, while revenue for the quarter reached $16.09M , beating expectations by +192.47%.
Earnings released on 10 Nov 2021
EPS came in at -$0.51 surpassing the estimated -$0.85 by +40.00%, while revenue for the quarter reached $54.99K , missing expectations by -20.63%.
Earnings released on 5 Aug 2021
EPS came in at -$1.36 falling short of the estimated -$0.85 by -60.00%.
Earnings released on 6 May 2021
EPS came in at -$0.68 falling short of the estimated -$0.05 by -1.26K%.
Earnings released on 11 Mar 2021
EPS came in at -$1.02 matching the estimated -$1.02.
Earnings released on 10 Nov 2020
EPS came in at -$1.19 falling short of the estimated -$1.02 by -16.67%.
LPCN Stock Performance
Access detailed LPCN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.